CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—NanoMolecularDX announced it has acquired the assets of Nuclea Biotechnologies. Assets include all of the intellectual property, biological material, capital equipment, licenses, FDA approvals and allowances, marketing and customer materials, trademarks, and all relevant scientific data. NMDX began selling in May HER2/neu blood testing kits acquired from Nuclea.
Read More »